GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Cash Receipts from Deposits by Banks and Customers

Gilead Sciences (LTS:0QYQ) Cash Receipts from Deposits by Banks and Customers


View and export this data going back to 2018. Start your Free Trial

What is Gilead Sciences Cash Receipts from Deposits by Banks and Customers?

Cash Receipts from Deposits by Banks and Customers only applicable to companies reporting Cash Flow from Operations in direct method.


Gilead Sciences (LTS:0QYQ) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (LTS:0QYQ) » Definitions » Cash Receipts from Deposits by Banks and Customers
Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.